The Effect of State Copay Accumulator Bans on Premiums in Commercial Health Insurance Markets

Clicks: 31
ID: 332573
2026
Free PDF
Article Quality & Performance Metrics
Overall Quality
Not rated
Combines reader engagement with the AI quality analysis. This article has not been analysed, so there is no overall score — reader engagement is measured and shown alongside.
AI Quality Assessment
Not analyzed
Readership in this journal
Emerging

Ranked #12 of 168 articles by views in Health Affairs Scholar

Most read Least read

Bar heights use a square-root scale. Only the 120 most-read articles are drawn; the journal has 168 in total.

Mint this article as an NFT
Not yet minted

Create a permanent, verifiable on-chain record of this article on the Scimatic Network. The NFT is held in your Journament account, and you can withdraw it to your own wallet at any time.

5 SUSD one-off · no wallet required
Sign in to mint
Abstract
Abstract Background Copay cards are used by pharmaceutical manufacturers to lower patient out-of-pocket (OOP) costs and increase patient adherence. Pharmacy benefit managers (PBMs) assert these programs increase premiums. PBMs use accumulators to prevent these funds from counting toward patient deductibles or OOP maximums. Federal regulations prohibit accumulators in certain situations but are generally not enforced due to concerns that premiums will rise. Accumulators are banned in 27 states and the District of Columbia. This paper leverages state-level data to explore whether there is a relationship between state accumulator bans and premiums. Methods Using 2014-2024 Medical Loss Ratio (MLR) filing data for small and large group issuers and information on state policies, we used staggered difference-in-differences methods to estimate the effect of state bans on premiums. Results From 2020-2024, average premiums in states that enacted bans grew slower (20.8%) than in states that did not (24.2%). There was no statistically significant difference in average annual premiums in states with bans had bans not been implemented ($41.08 [95% CI: -$151.28 to $233.43]). This was consistent across specifications. Conclusion The evidence does not support concerns that copay accumulator bans increase premiums.
Reference Key
openalex_W7222445397 Use this key to autocite in the manuscript while using SciMatic Manuscript Manager or Thesis Manager
Authors Yevgeniy Feyman, Kimberly D. Westrich, William Sarraille, Rory Martin, David Choi, Jonathan D. Campbell
Are you one of these authors? Claim your profile
Journal Health Affairs Scholar
Year 2026
DOI
10.1093/haschl/qxag289
URL
https://doi.org/10.1093/haschl/qxag289
Keywords Keywords not found

Citations

No citations found. To add a citation, contact the admin at info@scimatic.org

Comments

No comments yet. Be the first to comment on this article.